search
Back to results

Chlorhexidine Gluconate Versus Povidone-Iodine as Vaginal Preparation Antiseptics Prior to Cesarean Delivery

Primary Purpose

Infection, Bacterial

Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Chlorhexidine Gluconate
Povidone-Iodine Scrub and Paint
Sponsored by
Metro Health, Michigan
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Infection, Bacterial

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Scheduled low transverse cesarean section (can be primary or repeat)
  • Term gestation ≥ 37 weeks

Exclusion Criteria:

  • Allergy to either antiseptic
  • Rupture of amniotic membranes
  • Preterm gestation
  • Active labor
  • Emergency or unscheduled cesarean sections
  • Infection diagnosis on admission
  • Vaginal infection or any treatment of vulvovaginitis in prior 7 days
  • Patients under the age of 18 years

Sites / Locations

  • Metro Health

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Chlorhexidine Gluconate

Povidone-Iodine Scrub and Paint

Arm Description

Pre-operative vagina preparation with Chlorhexidine Gluconate Intervention: Drug: Chlorhexidine Gluconate Other Name: Chlora-Prep

Pre-operative vagina preparation with Povidone-Iodine Scrub and Paint Intervention: Drug: Povidone-Iodine Scrub and Paint Other Name: Betadine

Outcomes

Primary Outcome Measures

Bacterial Load
Change in total bacterial load from baseline (pre-operative) vaginal culture

Secondary Outcome Measures

Length of Hospital Stay
Number of days

Full Information

First Posted
April 3, 2017
Last Updated
March 7, 2019
Sponsor
Metro Health, Michigan
search

1. Study Identification

Unique Protocol Identification Number
NCT03133312
Brief Title
Chlorhexidine Gluconate Versus Povidone-Iodine as Vaginal Preparation Antiseptics Prior to Cesarean Delivery
Official Title
A Single Site Prospective Randomized Controlled Trial Comparing Chlorhexidine Gluconate and Povidone-Iodine as Vaginal Preparation Antiseptics for Cesarean Section to Determine Effect on Bacterial Load
Study Type
Interventional

2. Study Status

Record Verification Date
March 2019
Overall Recruitment Status
Completed
Study Start Date
May 2, 2017 (Actual)
Primary Completion Date
December 30, 2017 (Actual)
Study Completion Date
December 30, 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Metro Health, Michigan

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Primary Hypothesis: chlorhexidine gluconate antiseptic vaginal preparation is superior to povidone-iodine vaginal preparation in decreasing the bacterial load within the vagina when prepping prior to a cesarean section.
Detailed Description
Patients who are planning cesarean will be recruited and consented for study participation at time of admission to labor and delivery. Patients undergoing cesarean who meet inclusion/exclusion criteria will be randomized to one of two surgical preparations as follows: 1. Chlorhexidine gluconate (CHG); or, 2. Povidone-iodine scrub. Randomization will be performed by the consenting surgeon (listed as key personnel) after the patient has arrived into the operating room for cesarean. To establish baseline bacterial load, a qualitative BAL culture will be collected prior to the vaginal preparations. Pre-operative surgical site antisepsis will be performed according to randomization. All other surgical practices will remain at the surgeon's discretion according to standard of care at Metro Health Hospital. At the completion of the cesarean, it is standard practice to perform a manual evacuation of blood clots from the lower uterine segment. The study culture will be obtained by the consenting surgeon immediately prior to manual evacuation. The cultures will then be sent to the lab for determination of total bacterial load of the vaginal area. The lab will be blinded toward which type of vaginal prep was used. Total colony count will be determined by certified lab personnel by adding all counts regardless of bacteria type. A secondary chart review will be performed by the investigator within 30 days of the postoperative period to evaluate for length of hospital stay, pain level, blood loss, any additional antibiotics received postoperatively, and the development of post-operative infection in subjects up to 30 days after discharge. The research project will take place over a 12-month period of time at Metro Health Hospital. In review of Metro Health Labor and Delivery statistics for scheduled cesarean sections performed in 2016, an average of 18.8 were performed a month, giving a total of approximately 226 in a one-year period. Based on the research study published by Culligan, Kubik, Murphy, et al. comparing the two vaginal preparations for vaginal hysterectomy, an estimated sample size was calculated. Using the 90 minute colony counts of 20,472 (40,058) vs 1,221 (2,857), and using an alpha of .05 and power of 80% investigator found the sample size for each group should be at least 27. This sample size (27 X 2 groups) is very close to the sample size (50) in the Culligan experiment. In an attempt to ensure the most clinically significant, investigators anticipate screening between 70-100 patients with approximately 70-80% participation. Analysis will be performed by the investigators for completeness, accuracy, strict adherence to study protocol, safety, and statistical significance. The investigators are also subject to periodic audits by the Institutional Review Board (IRB).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Infection, Bacterial

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Model Description
Drug: Chlorhexidine Gluconate Applied to vagina pre-operatively for antiseptic; regulated as a drug by FDA Other Name: CHG Drug: Povidone-Iodine Scrub and Paint Applied to vagina pre-operatively for antiseptic; regulated as a drug by FDA Other Name: Betadine
Masking
ParticipantCare ProviderOutcomes Assessor
Masking Description
Participant will not know which group they have been assigned to. The surgeon and OR staff performing the vaginal preparation will know, but the nursing staff in the recovery area will not. The lab will be blinded toward which type of surgical prep was used.
Allocation
Randomized
Enrollment
100 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Chlorhexidine Gluconate
Arm Type
Experimental
Arm Description
Pre-operative vagina preparation with Chlorhexidine Gluconate Intervention: Drug: Chlorhexidine Gluconate Other Name: Chlora-Prep
Arm Title
Povidone-Iodine Scrub and Paint
Arm Type
Experimental
Arm Description
Pre-operative vagina preparation with Povidone-Iodine Scrub and Paint Intervention: Drug: Povidone-Iodine Scrub and Paint Other Name: Betadine
Intervention Type
Drug
Intervention Name(s)
Chlorhexidine Gluconate
Other Intervention Name(s)
Chlora-Prep
Intervention Description
Pre-operative vaginal preparation with 4% Chlorhexidine Gluconate Intervention
Intervention Type
Drug
Intervention Name(s)
Povidone-Iodine Scrub and Paint
Other Intervention Name(s)
Betadine
Intervention Description
Pre-operative vaginal preparation with 10% Povidone-Iodine Scrub and Paint Intervention
Primary Outcome Measure Information:
Title
Bacterial Load
Description
Change in total bacterial load from baseline (pre-operative) vaginal culture
Time Frame
Immediately Post-operative prior to exit from operating room
Secondary Outcome Measure Information:
Title
Length of Hospital Stay
Description
Number of days
Time Frame
2 or 3 post-operative days
Other Pre-specified Outcome Measures:
Title
Post-Operative Infection
Description
Presence of post-operative infection including endometritis, pelvic abscess, and skin/wound
Time Frame
up to 30 day post-operative

10. Eligibility

Sex
Female
Gender Based
Yes
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Scheduled low transverse cesarean section (can be primary or repeat) Term gestation ≥ 37 weeks Exclusion Criteria: Allergy to either antiseptic Rupture of amniotic membranes Preterm gestation Active labor Emergency or unscheduled cesarean sections Infection diagnosis on admission Vaginal infection or any treatment of vulvovaginitis in prior 7 days Patients under the age of 18 years
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Brad Irving, DO, FACOOG
Organizational Affiliation
Metro Health
Official's Role
Principal Investigator
Facility Information:
Facility Name
Metro Health
City
Wyoming
State/Province
Michigan
ZIP/Postal Code
49519
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
15695981
Citation
Culligan PJ, Kubik K, Murphy M, Blackwell L, Snyder J. A randomized trial that compared povidone iodine and chlorhexidine as antiseptics for vaginal hysterectomy. Am J Obstet Gynecol. 2005 Feb;192(2):422-5. doi: 10.1016/j.ajog.2004.08.010.
Results Reference
result
PubMed Identifier
20054046
Citation
Darouiche RO, Wall MJ Jr, Itani KM, Otterson MF, Webb AL, Carrick MM, Miller HJ, Awad SS, Crosby CT, Mosier MC, Alsharif A, Berger DH. Chlorhexidine-Alcohol versus Povidone-Iodine for Surgical-Site Antisepsis. N Engl J Med. 2010 Jan 7;362(1):18-26. doi: 10.1056/NEJMoa0810988.
Results Reference
result
PubMed Identifier
21323582
Citation
Levin I, Amer-Alshiek J, Avni A, Lessing JB, Satel A, Almog B. Chlorhexidine and alcohol versus povidone-iodine for antisepsis in gynecological surgery. J Womens Health (Larchmt). 2011 Mar;20(3):321-4. doi: 10.1089/jwh.2010.2391. Epub 2011 Feb 16.
Results Reference
result
PubMed Identifier
26844840
Citation
Tuuli MG, Liu J, Stout MJ, Martin S, Cahill AG, Odibo AO, Colditz GA, Macones GA. A Randomized Trial Comparing Skin Antiseptic Agents at Cesarean Delivery. N Engl J Med. 2016 Feb 18;374(7):647-55. doi: 10.1056/NEJMoa1511048. Epub 2016 Feb 4.
Results Reference
result
PubMed Identifier
32335895
Citation
Haas DM, Morgan S, Contreras K, Kimball S. Vaginal preparation with antiseptic solution before cesarean section for preventing postoperative infections. Cochrane Database Syst Rev. 2020 Apr 26;4(4):CD007892. doi: 10.1002/14651858.CD007892.pub7.
Results Reference
derived

Learn more about this trial

Chlorhexidine Gluconate Versus Povidone-Iodine as Vaginal Preparation Antiseptics Prior to Cesarean Delivery

We'll reach out to this number within 24 hrs